Anti-CD73 antibody and use thereof
AssigneeBiotheus Inc.
InventorsLiang Du, Hongyan Zhang, Lina Jin, Yali Chen, Jijun Yuan, Zhenqing Zhang, Xiaoniu Miao, Weifeng Huang, Yunli Jia
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of disease therapy and immunology. Specifically, disclosed are an anti-CD73 antibody or an antigen-binding fragment thereof, a nucleic acid molecule encoding same, an immunoconjugate comprising same, a bispecific molecule and a pharmaceutical composition, as well as use thereof in enhancing immune response and/or treating tumors.
Claims20
An antibody or antigen-binding fragment thereof capable of specifically binding to CD73, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein:
- (1) the VH comprises:
- VHCDR1 comprising the sequence set forth in SEQ ID NO:
- 3, VHCDR2 comprising the sequence set forth in SEQ ID NO:
- 4, VHCDR3 comprising the sequence set forth in SEQ ID NO:
- 5 and the VL comprises:
- VLCDR1 comprising a sequence set forth in SEQ ID NO:
- 6, VLCDR2 comprising the sequence set forth in SEQ ID NO:
- 7, and VLCDR3 comprising the sequence set forth in SEQ ID NO:
- 8 or,
- (2) the VH comprises three CDRs of the heavy chain variable region as shown in SEQ ID NO:
- 1;
- and the VL comprises three CDRs of the light chain variable region as shown in SEQ ID NO:
- 2;
- wherein the CDRs are defined by the Kabat, Chothia or IMGT numbering system.
Dependencies are inferred from the claim text.